DV Biomed held its shareholders' meeting on the 22nd, during which the 2024 annual business report and financial statements were approved. The meeting also approved a cash dividend of NT$1.8 and a stock dividend of NT$1.8 per share for the second half of last year. In total, DV Biomed distributed a cash dividend of NT$2.8 and a stock dividend of NT$1.8 per share for the entire year, amounting to a combined dividend of NT$4.6 per share. Looking ahead, the company maintains a cautiously optimistic outlook and, in response to the rapid transformation of global consumer market structures and the rise of the digital economy, will actively pursue operational upgrades with a focus on being data-driven, making intelligent decisions, diversifying sales channels, and expanding internationally.
DV Biomed noted that although last year's overall revenue was slightly lower than the previous year due to macroeconomic conditions, the company maintained strong performance by flexibly adjusting its marketing strategies, controlling expenses, deepening its digital transformation initiatives, and enhancing operational efficiency through effective resource integration. Net profit attributable to the parent company totaled NT$89.08 million, with earnings per share (EPS) of NT$4.93, reflecting stable profitability. In addition, the company completed the spin-off of its medical aesthetics service platform, which is expected to provide fresh momentum for future growth.
In terms of R&D and product innovation, DV Biomed continued to invest in the health supplements and skincare sectors. Last year, it rolled out several R&D projects, including the “Pure Enjoyment,” “Pure Perfection,” “Pure Radiance” product lines, and the “Superconductive Exosome Repair Miracle Serum,” showcasing its robust innovation capabilities and deep understanding of consumer needs for health and beauty. These product innovations not only expanded the company’s offerings but also strengthened its competitive edge in both the beauty care and health supplement markets.
Looking ahead, DV Biomed maintains a cautiously optimistic stance. The company is committed to operational upgrades in the face of the fast-evolving global consumer market and digital economy trends, and is advancing toward data-driven operations, smart decision-making, diversified channels, and global expansion. It has completed the initial build-out of its big data infrastructure and will further integrate AI and business intelligence to enhance the efficiency of its proprietary customer data platform, aiming to increase return on investment, optimize precision marketing, and reduce operational costs.
Meanwhile, DV Biomed is actively implementing a member value model and life cycle management system, leveraging LINE and social media platforms to enhance customer engagement and retention through tiered management and churn prediction. With the integration of data analytics and AI, the company expects to improve cost control, decision-making efficiency, and customer relationship management.
To align with new retail trends and the expansion of diversified channels, DV Biomed is also developing livestream commerce and self-media strategies, partnering with KOLs and internal consultants to boost real-time sales and market penetration. Additionally, to mitigate single-market risk and scale operations, the company has initiated a strategic overseas expansion plan, with the first phase targeting high-potential Chinese communities in Southeast Asia, steadily advancing its brand globalization. DV Biomed emphasized that it will continue to attract key talent, optimize production and sales efficiency, and strengthen member engagement, adopting a steady expansion strategy to respond to market shifts and create sustainable, long-term value for shareholders.
Resource: 麗彤啟動海外拓展計畫 今年營運審慎樂觀
